SoftBank Group Corp. has silently erected a USD5 billion stake in Roche Holding AG, putting a stake on the pharmaceutical company’s policy of using data to produce drugs, as per the ones concerned with the matter.The Japanese corporation has become one of Roche’s biggest investors, according to reports.
The pharmaceutical company’s sales have lately been increased by its Covid-19 testing trade. The Roche’s diagnostics division responded speedily to the coronavirus pandemic, but the pharma unit, where old cancer medicines face rising competition, has had tougher time.
According to an employee, SoftBank thinks Roche’s Genentech unit that centers on data-based drug sighting and development is much underrated. The Roche hired Aviv Regev last year, a computational and systems biologist who has formerly been Harvard University-affiliated Broad Institute’s central member, to be the lead of Genetech research division.Roche is working on developing a new drug for Alzheimer’s and Covid-19 disease treatment. The U.S. approved Alzheimer’s drug Aduhelm by Biogen Inc. in June 2021, which is considered being a positive indication for the Roche medicine.